V
Viridis BioSciences develops plant-derived oral supplements that function as Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs) for metabolic health support. The company leverages plant biotechnology to create stable, affordable alternatives to conventional injectable therapies for weight management and glycemic control. This platform bridges biotechnology and daily nutrition to provide accessible, non-invasive wellness solutions.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Viridis BioSciences develops plant-derived oral supplements that function as Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs) for metabolic health support. The company leverages plant biotechnology to create stable, affordable alternatives to conventional injectable therapies for weight management and glycemic control. This platform bridges biotechnology and daily nutrition to provide accessible, non-invasive wellness solutions.